Head-to-head · WeighScore
Fitstry vs JRNYS
The verdict
JRNYS takes it — 62.5/100 to 61.5/100, but only just.
JRNYS grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. JRNYS is a telehealth weight-loss membership built around branded GLP-1 medications, and the membership itself buys no medication. Fitstry is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fitstry | JRNYS |
|---|---|---|
| WeighScore | 61.5/100 | 62.5/100 |
| Grade | C | C |
| Scorecard rank | #292 | #267 |
| Semaglutide | $179/mo (annual plan, plus a separate fee, compounded) | Not disclosed |
| Tirzepatide | $269/mo (annual plan, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #292 · C
Strengths
- Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
- Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
- Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
- Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
- Full compounded lineup — weekly injection, daily oral tablet and microdosing options
Where it loses points
- Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
- Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Graded #267 · C
Strengths
- Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
- The membership band is published before intake and is banded openly by level of coach support
- Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
- Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
- Members with commercial insurance may pay around $25 a month for the medication after any deductible
Where it loses points
- The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
- No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
- The best case depends on commercial insurance coverage; without it the medication cost is unknown
- No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
- The states it can prescribe in are not published
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.